Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209]
1 Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
2 Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy.
3 Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
4 Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
5 Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy; University of Milano, Milan, Italy.
6 Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
7 Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Experimental Oncology, IEO, European Institute of Oncology IRCSS, Milan, Italy.
8 Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.